Biotech Earnings Watch: BSX, MEDP, MOH, TMO Set To Report Oct 22

Four key healthcare and biotech firms—Boston Scientific (BSX), Medpace Holdings (MEDP), Molina Healthcare (MOH), and Thermo Fisher Scientific (TMO)—are scheduled to release Q3 earnings on October 22, with their 2025 guidance poised to shape sector expectations. BSX projects 2025 organic net sales growth of 14-15% and adjusted EPS of $2.95-$2.99. Medpace, whose stock recently hit a 52-week high, anticipates 2025 revenue growth of 14.7-19.5% and GAAP EPS of $13.76-$14.53. Molina Healthcare expects 2025 premium revenue around $42 billion and adjusted EPS of at least $19.00, while Thermo Fisher forecasts 2025 revenue of $43.6-$44.2 billion and an increased adjusted EPS range of $22.22-$22.84.

Analysis

Four major healthcare and biotech firms—Boston Scientific (BSX), Medpace Holdings (MEDP), Molina Healthcare (MOH), and Thermo Fisher Scientific (TMO)—are scheduled to report Q3 earnings on October 22. These reports will offer critical insights into sector momentum and 2025 guidance, with the general market sentiment noted as moderately positive and optimistic.

Medpace Holdings (MEDP) exhibits strong positive sentiment (0.7), recently achieving a 52-week high on above-average volume, supported by 2025 revenue growth guidance of 14.7-19.5% and GAAP EPS forecasts of $13.76-$14.53. Thermo Fisher Scientific (TMO) also shows moderately positive sentiment (0.5), with its stock up 2.6% on strong volume, driven by an increased FY25 adjusted EPS guidance range of $22.22-$22.84.

Boston Scientific (BSX) projects robust full-year 2025 organic net sales growth of 14-15% and adjusted EPS of $2.95-$2.99, closely aligning with analyst consensus despite a slight stock dip. Molina Healthcare (MOH) maintains its 2025 premium revenue guidance at $42 billion, a 9% increase, and expects adjusted EPS of no less than $19.00, reflecting Marketplace and medical cost trend assumptions.

The varied performance and guidance across these sub-sectors—medical devices, CROs, managed healthcare, and life sciences solutions—highlight distinct growth drivers within the broader healthcare industry. Strong organic growth from BSX and MEDP, coupled with TMO's upward EPS revision, indicate underlying strength in specific market segments.

Key Decisions for Investors

• Investors should closely monitor Q3 results for Medpace Holdings and Thermo Fisher Scientific to confirm their strong guidance and recent positive stock momentum, evaluating any deviations from expectations.
• For Boston Scientific and Molina Healthcare, assess Q3 performance against current guidance and analyst estimates to determine if recent stock movements reflect fundamental shifts or temporary market reactions.
• Consider strategic allocation within the healthcare sector, prioritizing companies with clear organic growth trajectories and upward guidance revisions, given the overall optimistic sentiment.